Close
AZ TouchPoints News
The AZ TouchPoints Web site gives you direct access to AstraZeneca services and support. Here, you can easily find online sample ordering, formulary information, and patient education materials for select AstraZeneca medicines.
Go to About AZ TouchPoints
To learn more about AstraZeneca medicines, visit the AZ corporate site for a complete list of professional Web sites.
Go to Web site directory
Visit the AstraZeneca medical affairs Web site to get answers to questions about AZ products and medicines.
Go to AZ US Medical Information
How can we help you?
I want to Find My Representative
Sorry, there are no Personal Account Specialists currently available in your area.
|
If you would like information regarding products from AstraZeneca,
please call 1-888-692-9737, Monday through Friday, 8:30 am to 8:30 pm ET, excluding holidays.
|
Learn more about Personal Account Specialists
Connect with your Personal Account Specialist* about any topic - from sample eligibility to clinical information and managed market updates.
*Your Personal Account Specialist is an employee of TMS Health, a service partner of AstraZeneca.
We're sorry. Our system was unable to find your Personal Account Specialist at this time.
|
For immediate assistance, please call 1-888-692-9737 to speak with a representative.
|
Learn more about Personal Account Specialists
Connect with your Personal Account Specialist* about any topic - from sample eligibility to clinical information and managed market updates.
*Your Personal Account Specialist is an employee of TMS Health, a service partner of AstraZeneca.
I want a Representative to Call Me Now
Sorry, there are no Personal Account Specialists currently available.
If you would like information regarding products from AstraZeneca,
please call 1-888-692-9737, Monday through Friday, 8:30 am to
8:30 pm ET, excluding holidays.
Thank you. We've received your request. The next available Personal Account Specialist will call you momentarily at .
If this number is incorrect, please go back to the previous screen and reenter the correct number.
Go Back
NEXIUM Is the #1 Prescribed Branded Proton Pump (PPI) by Gastroenterologists1
NEXIUM® (esomeprazole magnesium), a proton pump inhibitor (PPI), has helped many people find relief from persistent heartburn. NEXIUM can also help heal damage to the esophagus that may be caused by acid reflux over time.2-7
This section contains important information about NEXIUM and prescribing considerations. You'll find complete information on dosage and administration as well as safety information. Click on the links below to access this information.
Next: Dosage & Administration for NEXIUM
See how much NEXIUM can cost the majority of your patients with prescription drug coverage for NEXIUM.
Learn more
Learn more about NEXIUM healing rates versus omeprazole and lansoprazole.
Get started now
Receive updates and offers from the maker of NEXIUM.
Register Now
Approved Uses
Healing of Erosive Esophagitis (EE)
NEXIUM 40 mg and NEXIUM 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed EE.
Maintenance of Healing of EE
NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE. Controlled studies did not extend beyond 6 months.
Symptomatic GERD
NEXIUM 20 mg is indicated for the short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD.
Pediatric Use
NEXIUM is indicated for the short-term treatment (up to 8 weeks) of GERD (symptomatic GERD and healing of EE) in patients 1 to 17 years of age. Pediatric use is supported by extrapolation of results from studies that supported the approval for NEXIUM for adults and safety and pharmacokinetic studies performed in pediatric and adolescent patients.
Effectiveness has not been demonstrated in patients less than 1 year of age. Safety and effectiveness for other pediatric uses have not been established.
Important Safety Information
- NEXIUM® (esomeprazole magnesium) is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
- In adult patients, the most frequently reported adverse events (AEs) with NEXIUM include headache, diarrhea, and abdominal pain
- In pediatric patients 1 to 17 years of age, the most frequently reported AEs with NEXIUM include headache, diarrhea, abdominal pain, nausea, and somnolence
- Symptomatic response to therapy does not preclude the presence of gastric malignancy
- Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which NEXIUM is an enantiomer
- Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. Esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg. ketoconazole, iron salts, and digoxin).
- Concomitant use of NEXIUM and atazanavir or nelfinavir is not recommended because the plasma concentrations and therapeutic effects of those antiretroviral drugs may be reduced
- NEXIUM may increase the plasma levels of saquinavir. Dose reduction of saquinavir should be considered
- NEXIUM may increase systemic exposure of cilostazol and an active metabolite. Consider dose reduction.
- NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information. Dosing for adults and pediatrics is provided in the Prescribing Information
Please click here for the full Prescribing Information 
(PDF – 303 KB) for NEXIUM.
Please see the full Prescribing Information available at the Web site for NEXIUM.
References
-
Data on File, eSTaR# 267691: IMS PlanTrak, July 2008 - June 2009 (last accessed August 17, 2009).
-
Prescribing Information for NEXIUM.
-
Labenz J, Armstrong D, Lauritsen K, et al. Aliment Pharmacol Ther. 2005;21:739-746.
-
Kahrilas PJ, Falk GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14:1249-1258.
-
Fennerty MB, Johanson JF, Hwang C, et al. Aliment Pharmacol Ther. 2005;21:455-463.
-
Castell DO, Kahrilas PJ, Richter JE, et al. Am J Gastroenterol. 2002;97:575-583.
-
Richter JE, Kahrilas PJ, Johanson J, et al. Am J Gastroenterol. 2001;96:656-665.
